| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
IC50: 4 nM (LMW-PTP)[1]
Low-molecular-weight protein tyrosine phosphatase (LMW-PTP), with IC50=4 nM and Ki=1.2 nM. Shows >8000-fold selectivity over other PTPs. |
|---|---|
| ln Vitro |
SPAA-52 exhibits equipotent activity across rat, mouse, and human LMW-PTP enzymes, with IC50 values of 3, 3, and 4 nM respectively. Its high selectivity (>8000-fold over other PTPs) makes it an excellent tool for specifically interrogating LMW-PTP function in biochemical assays.
|
| ln Vivo |
1.19 Plasma PK Parameters in Healthy Mice[1] Compound SPAA-52 dose route 2 mg/kg IV 10 mg/kg PO AUC (0−8 h) (nM h) 15,100 37,300 C0 or Cmax (nM) 13,400 9690 C0 or Cmax unbound (nM) 332 233 Vdss (L/kg) 0.42 CL (mL/min/kg) 5.65 T1/2 (h) 1.41 4.2 F (%) 34 1.19 Plasma PK Parameters in Healthy Rats[1] Compound SPAA-52 dose route 3 mg/kg PO AUC (0-12 h) (nM h) 4660 Cmax (nM) 877 Cmax unbound (nM) 21 Vdss (L/kg) 0.42 Tmax (h) 2.0 T1/2 (h) 2.4
In vivo activity has been reported in diabetes research contexts, though specific in vivo efficacy data are limited. As an orally active inhibitor, SPAA-52 can be administered orally to animal models to evaluate its effects on glucose metabolism, insulin signaling, and other diabetes-related parameters. |
| Enzyme Assay |
For enzyme inhibition assays, SPAA-52 is dissolved in DMSO and diluted in assay buffer. LMW-PTP enzyme is incubated with a fluorogenic substrate such as 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP) in the presence of varying inhibitor concentrations (0.1-100 nM). Fluorescence is measured (excitation ~360 nm, emission ~460 nm) and IC50/Ki values are determined from dose-response curves.
|
| Cell Assay |
For cellular assays, cells are treated with SPAA-52 at concentrations ranging from 1 nM to 10 microM for 24-72 hours. LMW-PTP activity in cell lysates can be measured using DiFMUP substrate. Cellular readouts may include insulin signaling markers (e.g., AKT phosphorylation) or glucose uptake assays in appropriate cell lines.
|
| Animal Protocol |
SPAA-52 is administered orally to rodent models of diabetes or metabolic syndrome. Dosing regimens typically range from 1-30 mg/kg once daily. Blood glucose levels, insulin sensitivity (via glucose tolerance tests), and body weight are monitored. Tissues are collected for analysis of LMW-PTP activity and downstream signaling pathways.
|
| ADME/Pharmacokinetics |
SPAA-52 is orally bioavailable with excellent solubility in DMSO (10 mM). Pharmacokinetic parameters such as half-life, Cmax, and AUC are consistent with oral administration. Detailed PK data are available in the literature (J Med Chem. 2022 Oct 27;65(20):13892-13909).
|
| Toxicity/Toxicokinetics |
Toxicological data for SPAA-52 have not been extensively published. As an investigational research compound with sub-micromolar potency, it should be handled following standard laboratory safety protocols. No human toxicity data are available as the compound is for research use only.
|
| References | |
| Additional Infomation |
SPAA-52 (CAS: 2837000-75-4) has a molecular formula of C8H8Br2N2O4S and molecular weight of 388.03. It is a valuable chemical probe for studying LMW-PTP function in diabetes and metabolic diseases. It is not approved for therapeutic use and is intended for research applications only.
|
| Molecular Formula |
C8H8BR2N2O4S
|
|---|---|
| Molecular Weight |
388.03311920166
|
| Exact Mass |
387.855
|
| CAS # |
2837000-75-4
|
| PubChem CID |
165413065
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
372
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C=C(C=C1Br)NC(=O)NS(=O)(=O)O)Br
|
| InChi Key |
XBWKZLBEUSPLFY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H8Br2N2O4S/c1-4-6(9)2-5(3-7(4)10)11-8(13)12-17(14,15)16/h2-3H,1H3,(H2,11,12,13)(H,14,15,16)
|
| Chemical Name |
(3,5-dibromo-4-methylphenyl)carbamoylsulfamic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (257.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5771 mL | 12.8856 mL | 25.7712 mL | |
| 5 mM | 0.5154 mL | 2.5771 mL | 5.1542 mL | |
| 10 mM | 0.2577 mL | 1.2886 mL | 2.5771 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
